Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ARIX BIOSCIENCE PLC Report Publication Announcement 2022

Jun 22, 2022

4968_rns_2022-06-22_6ad81a07-c79b-4b3f-a478-3992f6c1b1b7.html

Report Publication Announcement

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

Arix Bioscience PLC (ARIX)

Notice of Investor Presentation

22-Jun-2022 / 07:00 GMT/BST

Dissemination of a Regulatory Announcement, transmitted by EQS Group.

The issuer is solely responsible for the content of this announcement.


Arix Bioscience plc

Notice of Investor Presentation

LONDON, 22 June 2022: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), announces that CEO, Robert Lyne, and Managing Director, Mark Chin, will be hosting a live presentation and Q&A session via the online platform, Investor Meet Company, at 1:00 p.m. BST on Wednesday 29 June 2022.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the 'Investor Meet Company' dashboard up until 9:00 a.m. on Tuesday 28 June 2022 or at any time during the live presentation. Investors can sign up to Investor Meet Company for free via: https://www.investormeetcompany.com/arix-bioscience-plc/register-investor

Investors who already follow Arix on the Investor Meet Company platform will automatically receive an invitation to the event.

[ENDS]

Enquiries

For more information on Arix, please contact:

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

[email protected]

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com


ISIN: GB00BD045071
Category Code: MSCL
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 169801
EQS News ID: 1380689
End of Announcement EQS News Service

fncls.ssp?fn=show_t_gif&application_id=1380689&application_name=news&site_id=fca